JP2013508289A5 - - Google Patents

Download PDF

Info

Publication number
JP2013508289A5
JP2013508289A5 JP2012534359A JP2012534359A JP2013508289A5 JP 2013508289 A5 JP2013508289 A5 JP 2013508289A5 JP 2012534359 A JP2012534359 A JP 2012534359A JP 2012534359 A JP2012534359 A JP 2012534359A JP 2013508289 A5 JP2013508289 A5 JP 2013508289A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
nitrite
composition according
plasma concentration
maintained
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012534359A
Other languages
English (en)
Japanese (ja)
Other versions
JP5758904B2 (ja
JP2013508289A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/052683 external-priority patent/WO2011047161A1/en
Publication of JP2013508289A publication Critical patent/JP2013508289A/ja
Publication of JP2013508289A5 publication Critical patent/JP2013508289A5/ja
Application granted granted Critical
Publication of JP5758904B2 publication Critical patent/JP5758904B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012534359A 2009-10-14 2010-10-14 ニトライトの医薬製剤及びそれらの使用 Expired - Fee Related JP5758904B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25148309P 2009-10-14 2009-10-14
US61/251,483 2009-10-14
PCT/US2010/052683 WO2011047161A1 (en) 2009-10-14 2010-10-14 Pharmaceutical formulations of nitrite and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015113882A Division JP6125567B2 (ja) 2009-10-14 2015-06-04 ニトライトの医薬製剤及びそれらの使用

Publications (3)

Publication Number Publication Date
JP2013508289A JP2013508289A (ja) 2013-03-07
JP2013508289A5 true JP2013508289A5 (https=) 2013-10-31
JP5758904B2 JP5758904B2 (ja) 2015-08-05

Family

ID=43855036

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012534359A Expired - Fee Related JP5758904B2 (ja) 2009-10-14 2010-10-14 ニトライトの医薬製剤及びそれらの使用
JP2015113882A Expired - Fee Related JP6125567B2 (ja) 2009-10-14 2015-06-04 ニトライトの医薬製剤及びそれらの使用
JP2017074888A Pending JP2017141275A (ja) 2009-10-14 2017-04-05 ニトライトの医薬製剤及びそれらの使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015113882A Expired - Fee Related JP6125567B2 (ja) 2009-10-14 2015-06-04 ニトライトの医薬製剤及びそれらの使用
JP2017074888A Pending JP2017141275A (ja) 2009-10-14 2017-04-05 ニトライトの医薬製剤及びそれらの使用

Country Status (10)

Country Link
US (4) US10463689B2 (https=)
EP (1) EP2488035B1 (https=)
JP (3) JP5758904B2 (https=)
CN (2) CN107260756A (https=)
AU (1) AU2010306755B2 (https=)
CA (1) CA2777066C (https=)
ES (1) ES2633618T3 (https=)
IL (1) IL219155A0 (https=)
IN (1) IN2012DN03428A (https=)
WO (1) WO2011047161A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008322437B2 (en) 2007-11-15 2013-11-07 Louisiana State University Use of nitrite salts in chronic ischemia
US20120237617A1 (en) 2009-06-18 2012-09-20 Theravasc Inc. Use of nitrite salts in treating tissue damage
ES2633618T3 (es) 2009-10-14 2017-09-22 Theravasc Inc. Formulaciones farmacéuticas de nitrito y sus usos
MX388990B (es) 2011-08-17 2025-03-20 Univ Texas Método de producción de niveles fisiológicos y terapéuticos de óxido nítrico por medio de un sistema de suministro oral.
US8627204B2 (en) * 2011-10-18 2014-01-07 Microsoft Corporation Custom optimization of web pages
WO2014130691A2 (en) 2013-02-20 2014-08-28 Theravasc Inc. Pharmaceutical formulations of nitrite and uses thereof
CN105339006A (zh) * 2013-05-10 2016-02-17 尼特罗米加公司 含有脂肪酸和亚硝酸盐的营养或膳食补充剂
GB201309092D0 (en) 2013-05-20 2013-07-03 Edixomed Ltd Transdermal delivery system
US20170349438A1 (en) 2016-06-06 2017-12-07 Theravasc Inc. Pharmaceutical formulations of nitrite and uses thereof
WO2018152509A1 (en) * 2017-02-20 2018-08-23 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Hydrogen sulfide and/or nitrite in the treatment and prevention of atrial fibrillation
US11850271B1 (en) * 2023-05-16 2023-12-26 King Faisal University Topical skin cream
WO2026006722A1 (en) 2024-06-28 2026-01-02 The Regents Of The University Of Michigan Nitric oxide generating medical devices and methods

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2914446A (en) * 1958-06-26 1959-11-24 Upjohn Co Nitrite stabilized ascorbic acid-cyanocobalamin compositions
US4650484A (en) 1983-02-03 1987-03-17 Alza Corporation Method for treating ischemic conditions
IE64726B1 (en) 1987-11-20 1995-08-23 Elan Corp Plc Pharmaceutical formulations for preventing drug tolerance
US5122384A (en) 1989-05-05 1992-06-16 Kv Pharmaceutical Company Oral once-per-day organic nitrate formulation which does not induce tolerance
US5278192A (en) 1992-07-02 1994-01-11 The Research Foundation Of State University Of New York Method of vasodilator therapy for treating a patient with a condition
US6709681B2 (en) 1995-02-17 2004-03-23 Aberdeen University Acidified nitrite as an antimicrobial agent
US20110196039A9 (en) * 1994-10-05 2011-08-11 Kaesemeyer Wayne H Controlled release arginine formulations
US5648101A (en) 1994-11-14 1997-07-15 Tawashi; Rashad Drug delivery of nitric oxide
US5770645A (en) 1996-08-02 1998-06-23 Duke University Medical Center Polymers for delivering nitric oxide in vivo
US5994444A (en) * 1997-10-16 1999-11-30 Medtronic, Inc. Polymeric material that releases nitric oxide
US7371415B1 (en) 1998-04-03 2008-05-13 The Daily Wellness Company Method and composition for improving sexual fitness
US7015876B1 (en) * 1998-06-03 2006-03-21 Lear Corporation Heads-up display with improved contrast
WO2000003725A1 (en) 1998-07-14 2000-01-27 Paracelsian, Inc. Method for identifying and confirming consistent bio-functionality of natural compositions
DE59905248D1 (de) 1999-01-29 2003-05-28 Disphar Int Bv Pharmazeutische zusammensetzungen
GB9905425D0 (en) 1999-03-09 1999-05-05 Queen Mary & Westfield College Pharmaceutical composition
US6314956B1 (en) 1999-09-08 2001-11-13 Duke University Pulmonary delivery of NO group-containing compound in gas form to treat respiratory, cardiac and blood disorders
GB0119011D0 (en) 2001-08-03 2001-09-26 Univ Aberdeen Treatment of nail infections
EP1492509A1 (en) 2001-12-18 2005-01-05 ALZA Corporation Dosage form providing time-varying patterns of drug delivery
EP1336602A1 (en) 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
JP2005524676A (ja) * 2002-03-20 2005-08-18 ザ・ユニバーシティ・オブ・クイーンズランド 一酸化窒素供与体及びオピオイド鎮痛薬を含む方法及び組成物
CA2379211A1 (fr) 2002-03-28 2003-09-28 Institut De Cardiologie De Montreal Utilisation du bleu de methylene pour renverser la reaction hemodynamique exageree induite par la combinaison d'un derive nitre et du sildenafil ou d'une molecule de meme classe (inhibiteur de la phosphodiesterase)
JP5564158B2 (ja) * 2003-07-09 2014-07-30 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ 亜硝酸塩によって特定の心臓血管状態を処置する方法
JP2007502831A (ja) 2003-08-20 2007-02-15 ニトロメッド インコーポレーティッド ニトロソ化およびニトロシル化心血管化合物、組成物、ならびに使用方法
US20050113409A1 (en) 2003-09-03 2005-05-26 Pharmacia Corporation Method for the prevention or treatment of pain, inflammation and inflammation-related disorders with a Cox-2 selective inhibitor in combination with a nitric oxide-donating agent and compositions therewith
US7362274B1 (en) 2004-07-09 2008-04-22 Huan-Cheng Lien Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna
US20060083824A1 (en) 2004-10-20 2006-04-20 Pbm Products Llc Nutritional supplements for glucose intolerant individuals
PL1846058T3 (pl) 2005-02-11 2009-12-31 Nolabs Ab Produkt, sposób i zastosowanie go do leczenia neuropatii z wydzielaniem tlenku azotu
CN101227916A (zh) 2005-05-24 2008-07-23 维尔金有限公司 预防和治疗发炎相关状况的组合物和方法
BRPI0621321A2 (pt) * 2006-02-10 2011-12-06 Mannatech Inc formulações de suplemento dietético de multivitamìnico e multimineral natural para melhor absorção e utilização biológica
GB0607402D0 (en) 2006-04-12 2006-05-24 Barts & London Nhs Trust Therapeutic composition and use
US8333997B2 (en) 2006-06-21 2012-12-18 Albert Einstein College Of Medicine Of Yeshiva University Compositions for sustained release of nitric oxide, methods of preparing same and uses thereof
DK2124638T3 (en) 2007-02-26 2017-03-20 Heartbeet Ltd COMPOSITION INCREASING PERFORMANCE AND USING IT
KR20100014853A (ko) 2007-02-26 2010-02-11 존 런드버그 아질산염 및 질산염의 신규 용도 및 이를 함유하는 조성물
WO2008153762A2 (en) 2007-05-25 2008-12-18 N30 Pharmaceuticals, Llc S-nitrosothiol formulations and storage systems
WO2009021058A2 (en) * 2007-08-06 2009-02-12 Trinity Labortories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
AU2008322437B2 (en) 2007-11-15 2013-11-07 Louisiana State University Use of nitrite salts in chronic ischemia
EP2237788A4 (en) * 2007-12-27 2013-06-05 Aires Pharmaceuticals Inc COMPOUNDS FOR OBTAINING AEROSOLIZED NITRITE AND NITRIC OXIDE AND USES THEREOF
WO2010036236A1 (en) 2008-09-23 2010-04-01 Baker Hughes Incorporated Anchor assembly
US8568793B2 (en) * 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
US20120237617A1 (en) 2009-06-18 2012-09-20 Theravasc Inc. Use of nitrite salts in treating tissue damage
ES2633618T3 (es) 2009-10-14 2017-09-22 Theravasc Inc. Formulaciones farmacéuticas de nitrito y sus usos
US20130209584A1 (en) 2009-10-14 2013-08-15 Theravasc Inc. Pharmaceutical formulations of nitrite and uses thereof
US20140127329A1 (en) 2011-03-31 2014-05-08 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Use of nitrites for the treatment of cerebral amyloid angiopathy, age associated dementia, and cognitive decline
US20140112983A1 (en) 2011-04-14 2014-04-24 Theravasc Inc. Nitrite compositions and uses thereof
US9294956B2 (en) 2011-12-29 2016-03-22 Qualcomm Incorporated Application-server-assisted preemptive multicast bearer establishment for real-time low-latency applications

Similar Documents

Publication Publication Date Title
JP2013508289A5 (https=)
HRP20250480T1 (hr) Kombinacija dasatiniba i adagrasiba za primjenu u liječenju nesitnostaničnog raka pluća
JP2010518122A5 (https=)
RU2012147739A (ru) Пероральные составы, содержащие аналоги цитидина, и способы их использования
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
JP2012502015A5 (https=)
JP2012502047A5 (https=)
HK1221646A1 (zh) 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
NZ625592A (en) Compositions and methods for the treatment of hepatic diseases and disorders
JP2012180381A5 (https=)
JP2012193216A5 (https=)
JP2015038135A5 (https=)
MX2011007779A (es) Formulaciones galenicas de compuestos organicos.
WO2011118976A3 (en) Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same
RU2011152105A (ru) Составы таблеток 3-цианохинолина и их применение
WO2009034431A3 (en) Controlled-release dosage forms for varenicline
SI2760821T1 (en) A salt salt of an anti-inflammatory substituted cyclobutenedione compound
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
JP2014503593A5 (https=)
JP2009513713A5 (https=)
WO2012020301A3 (en) Oral controlled release pharmaceutical compositions of blonanserin
NZ611026A (en) Pharmaceutical composition comprising citrate and bicarbonate salts, and use thereof for treating cystinuria
WO2007145863A3 (en) Sustained release formulation of naltrexone
JP2016512247A5 (https=)
JP2016505050A5 (https=)